Tiziana Life Sciences (NASDAQ:TLSA) Announces Quarterly Earnings Results

Tiziana Life Sciences (NASDAQ:TLSA) posted its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, FiscalAI reports.

Tiziana Life Sciences Stock Performance

Shares of TLSA stock remained flat at $1.05 during trading on Friday. 558,773 shares of the company were exchanged, compared to its average volume of 693,815. The stock has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.16. Tiziana Life Sciences has a 12 month low of $0.76 and a 12 month high of $2.10.

Wall Street Analyst Weigh In

TLSA has been the topic of a number of recent analyst reports. Wall Street Zen cut Tiziana Life Sciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Tiziana Life Sciences in a report on Wednesday, August 26th. Zacks Research raised shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Tiziana Life Sciences in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tiziana Life Sciences has a consensus rating of “Hold”.

Insiders Place Their Bets

In other Tiziana Life Sciences news, CEO Ivor Elrifi bought 667,000 shares of the stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $1.00 per share, with a total value of $667,000.00. Following the acquisition, the chief executive officer directly owned 4,472,261 shares of the company’s stock, valued at $4,472,261. The trade was a 17.53% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 988,423 shares of company stock valued at $985,909. 39.82% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC increased its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 12.0% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 111,900 shares of the company’s stock after purchasing an additional 12,000 shares during the period. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $131,000 as of its most recent SEC filing.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing therapies that regulate the immune system and address inflammatory and neurodegenerative diseases. The company’s research centers on treatments designed to modulate immune responses without broadly suppressing immune function.

Tiziana’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells. The company is developing an intranasal formulation of foralumab for conditions associated with neuroinflammation, including non-active secondary progressive multiple sclerosis and Alzheimer’s disease.